Synopsis: John LaMattina is the former President of Global R&D at Pfizer and is currently a Senior Partner at PureTech Health. A self-proclaimed defender of the pharmaceutical industry, Dr. LaMattina worked at Pfizer for 30 years before joining the biotech industry as a board member for a variety of different biotech companies. His recently published book, “Pharma and Profits”, talks about the misconceptions around COVID-19 vaccines and other areas including the cost of drugs, and the impact that the passing of the IRA Act will have on R&D going forward. In this episode he also discusses how biotech leaders should be thinking about the new IRA Act legislation and what changes they should anticipate. Biography: Dr. John L. LaMattina is the former Senior Vice President, Pfizer Inc and President, Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of over 13,000 colleagues in the United States, Europe and Asia. He retired from this position in December, 2007. Dr. LaMattina spent 30 years at Pfizer Inc having joined as a medicinal chemist in 1977. Over the years, he held positions of increasing responsibility for Pfizer Central Research, including Vice President of US Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999. Dr. LaMattina graduated cum laude from Boston College in 1971 with a B.S. in Chemistry. He attended the University of New Hampshire receiving a Ph.D. in Organic Chemistry in 1975. He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor. During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS. Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents. In addition, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D and Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image? He is also a Forbes contributor. Dr. LaMattina has received a number of awards including the 1998 Boston College Alumni Award of Excellence in Science, the 2007 Equal Opportunity Award from Legal Momentum, an Honorary Doctor of Science degree from the University of New Hampshire and the 2010 American Chemical Society Earle Barnes Award for Leadership in Chemical Research Management. Dr. LaMattina is a Senior Partner and a member of the Board of Directors of PureTech Health. He serves on the Board of Directors of Ligand Pharmaceuticals, Immunome and Vedanta. Dr. LaMattina also serves as a Trustee Associate on the Board of Trustees of Boston College.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related